Illustrative image – not actual.
Bharat Biotech International and the University of Sydney Infectious Diseases Institute (Sydney ID) have signed a memorandum of understanding (MoU) to advance vaccine research initiatives. It would also strengthen academic-industry partnerships and augment global efforts to combat infectious diseases.
The pact is for building strong sectoral and cross-organisational collaborations towards designing novel methodologies to tackle future epidemics and infectious diseases.
Furthermore, it aims to leverage academia-industry strengths for advancing the science of vaccines and biotherapeutics. The agreement would facilitate collaborative research, foster innovation, and further advance the science vaccine technology, as new opportunities emerge to leverage education, and research capabilities to develop safer vaccine platforms.
The collaboration would also help build the talent of young scientists. The focus is on developing novel vaccines which are safe, affordable, and effective.
India’s capabilities in vaccine manufacturing came out during the Covid-19 pandemic, where companies such as Bharat Biotech, provided vaccines that met over 60 percent of the world’s demand and supplied over 2.4 billion doses of Covid-19 vaccines.
